New Bacteria-Based cream aims to soothe cancer drug rash
NCT ID NCT06830863
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a cream called ATR04-484 for treating moderate to severe skin rash that can happen when taking EGFR inhibitor cancer drugs. The cream contains a specially engineered bacteria. 32 adults will apply the cream or a placebo daily for 28 days to see if it is safe and helps clear the rash.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ATR04-484, a cream containing engineered bacteria
- What this could lead to
- If it works, this could provide a new topical treatment for the painful skin rash caused by certain cancer drugs.
- What could go wrong
- This is an early phase 1/2 trial with only 32 people, so results may not apply to everyone. The cream may not work better than the placebo (vehicle) cream.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EGFR INHIBITOR-ASSOCIATED RASH are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Genesis Cancer and Blood Institute
RECRUITINGHot Springs, Arkansas, 71913, United States
-
Inova Schar Cancer
RECRUITINGFairfax, Virginia, 22031, United States
-
MD Anderson
RECRUITINGHouston, Texas, 77030, United States
-
NYU Langone
RECRUITINGNew York, New York, 10016, United States
-
The Ohio State University
RECRUITINGGahanna, Ohio, 43230, United States
-
Yale University School of Medicine
RECRUITINGNew Haven, Connecticut, 06510, United States